Document is current

Feasibility of dc vaccine combined with low dose endoxan and high dose il-2 treatment associated with taurolidine for advanced, multi-resistant melanoma patients.

Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P209

Published Online: 2015-11-04

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy